Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q1 2024 Earnings Conference
The following is a summary of the Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript:
以下是Acumen製藥公司（ABOS）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Acumen Pharmaceuticals reported cash and marketable securities worth approximately $297 million at the end of Q1 2024.
R&D expenses for the quarter rose to $12.4 million due to costs related to the ALTITUDE-AD trial.
The company's Q1 G&A expenses increased to $5.3 million due to increased headcount, resulting in an operational loss of $17.8 million for the quarter.
Acumen Pharmicals報告稱，截至2024年第一季度末，現金和有價證券價值約2.97億美元。
由於與ALTITUDE-AD試驗相關的成本，本季度的研發費用增至1,240萬美元。
由於員工人數的增加，該公司第一季度的併購支出增加到530萬美元，導致該季度的運營虧損爲1,780萬美元。
Business Progress:
業務進展：
The first patient has been dosed in the ALTITUDE-AD Phase II study, which trials the effectiveness and safety of sabirnetug.
Positive feedback has been received on the Phase I INTERCEPT results, particularly on patient biomarker improvements.
A Phase I study is planned for a subcutaneous formulation of sabirnetug, which should be launched in mid-2024.
The company has established a collaboration with Lonza for the manufacturing of sabirnetug, leveraging the latter's regulatory knowledge and global manufacturing network.
在ALTITUDE-AD II期研究中，第一位患者服用了劑量，該研究試驗了sabirnetug的有效性和安全性。
已收到有關I期INTERCEPT結果的積極反饋，特別是患者生物標誌物改善的反饋。
計劃對sabirnetug的皮下製劑進行一項I期研究，該製劑將於2024年中期啓動。
該公司已與Lonza建立了合作關係，利用後者的監管知識和全球製造網絡，生產sabirnetug。
More details: Acumen Pharmaceuticals IR
更多詳情： Acumen 製藥公司 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。